Wedbush raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $7 and keeps an Outperform rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Midday Fly By: Target reports mixed Q3, Adobe buying Semrush
- Nuvation Bio initiated with a Buy at B. Riley
- Positive Outlook on Nuvation Bio’s Safusidenib Driven by Promising Clinical Data and Strategic Focus
- Nuvation Bio Reports Positive Phase 2 Study Results
- Nuvation Bio’s Strategic Dilemma: Navigating Taletrectinib’s Global Commercialization Risks